The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...
The FDA is reportedly down to a handful of final candidates to lead CBER, with a potential selection expected in the coming ...
Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...
As Q1 earnings roll in, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least ...
A subsidiary of Indian drugmaker Hetero Group mistakenly packaged two types of antidepressants in packs of sertraline, ...
Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than ...
Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include ...
Amid disruption to the outsourced fill/finish market, PCI is investing $100 million to more than double the capacity to fill ...
Candid Therapeutics follows closely behind Neurona Therapeutics, which UCB acquired in mid-April in a potential $1.15 billion ...
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results